Brazil Senate discusses pathways for advancement of clinical research

20 March 2014

The Brazilian Senate's Social Affairs Committee (CAS) held a hearing on March 18 to debate the progress and challenges of clinical research of medicines in Brazil. The event was attended by representatives of the government's regulatory agencies involved in human clinical research as well as and members of the scientific communities in the country, says Juliane Carvalho writing on Brazil Pharma News.

One of the issues most frequently mentioned by the representatives of the scientific reps was the need to accelerate the analysis of clinical research for the country to be able to participate in a larger number of studies. Nowadays, human clinical research takes place simultaneously in several countries.

According to ANVISA (Brazil's National Health Surveillance Agency) Chief Commissioner Dirceu Barbano, clinical research is fundamental to people's access to new drugs and the development of a national industry for drugs but it is necessary to adopt all necessary precautions to ensure that the rights and safety of volunteers in research are guaranteed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK